Company profile
COSCIENS Biopharma Inc.
OTC: CSCIF · Healthcare · Medical - Pharmaceuticals
Canadian filerHQ Toronto, ONReports USD
#666 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
43DFH 46DQ —GM 30SS 54
v0.1 · 45/100 weight · provisional
↑ listing tenure, Piotroski F · ↓ return on equity, revenue growth (YoY)
Methodology →Revenue TTM
$8.3M
Rev growth YoY (TTM)
-11.3%
Net income (FY)
-$10.5M
Employees
28
as of 2026-08-23
Market cap
$1.9M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$7.6M$7.6M2025
Net income-$10.5M-$10.5M2025
Operating income-$10.6M-$10.6M2025
Total assets$21.4M$21.4M2025
Liabilities$17.5M$17.5M2025
Equity$3.8M$3.8M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is COSCIENS Biopharma Inc.’s revenue?
COSCIENS Biopharma Inc. booked $7.6M in FY2025 revenue, contracting 45% year over year — slower than 80% of Healthcare companies we track, at a -138.1% net margin.
Peers · Healthcare
Bolt Biotherapeutics, Inc.39DBeyond Air, Inc.42DAmazonas Florestal, Ltd——CompuMed, Inc.69BXenon Pharmaceuticals Inc.56COvid Therapeutics Inc.49DKey facts
CEOPeter Harry Puccetti
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersToronto, ON
ExchangeOTC: CSCIF
Employees28
IPO date2000-05-10
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.